Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.

Intermediate-grade and touching TILs may be good variables to examine in the COMET trial and to correlate with the risk of upgrading.